NASDAQ: $SOPH
In a significant move for the future of precision medicine, the Mount Sinai Health System has announced a strategic collaboration with SOPHiA GENETICS. This partnership marks a new chapter for one of the nation’s most prestigious academic health systems, as it integrates the AI-powered SOPHiA DDM™ Platform to refine its genomic testing capabilities for oncology patients.
A Commitment to Genomic Excellence
Mount Sinai, recognized as a National Cancer Institute-designated Comprehensive Cancer Center, provides care for over 4,000 oncology patients each year. As the complexity of cancer genomics grows, the need for robust, efficient analysis tools has never been higher. By adopting the SOPHiA DDM™ Platform, Mount Sinai’s Molecular Pathology team aims to strengthen its next-generation sequencing (NGS) workflows, specifically focusing on solid tumors and blood cancers.
The platform is engineered to streamline the detection and interpretation of complex genomic variants. By consolidating critical stages of the analysis pipeline, the technology reduces manual interpretation time, allowing laboratory professionals to focus on the high-level decision-making required for personalized treatment plans.
The Impact on Clinical Workflows
Jane Houldsworth, Ph.D., Director of Molecular Oncology Pathology at Mount Sinai, highlighted the practical advantages of this integration. “The collaboration between Mount Sinai and SOPHiA GENETICS reinforces our commitment to scientific innovation by integrating powerful digital tools into our workflows to support high-quality, data-driven cancer care,” said Dr. Houldsworth. “Leveraging SOPHiA DDM™ has enabled us to reduce hands-on analysis time and improve our testing turnaround times, enabling our clinicians to provide better patient care.”
Leading with AI
The partnership highlights Mount Sinai’s position as a leader in healthcare innovation. Having been ranked No. 1 globally among health care institutions in the Nature AI Index, Mount Sinai continues to prioritize the intersection of artificial intelligence and medicine. John Carey, Managing Director, North America at SOPHiA GENETICS, noted the significance of this alignment: “We are honored to support their teams with an AI-native platform and global network designed to deliver faster results, greater operational efficiency, and deeper genomic understanding to help shape the future of precision oncology.”
Building a Global Network
By implementing SOPHiA DDM™ for both blood cancers and solid tumors, Mount Sinai becomes part of an expansive global network of more than 990 institutions. This decentralized approach is central to the mission of SOPHiA GENETICS—democratizing data-driven medicine through cloud-native solutions. As hospitals around the world work to keep pace with the rapid evolution of genomic research, collaborations like this provide the scalable infrastructure necessary to turn complex data into actionable clinical insights, ultimately fostering better outcomes for patients worldwide.